Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD)

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 9, 2012, Pages 748-755

  Leonardis, D ^a   Basta, G ^b   Mallamaci, F ^a   Cutrupi, S ^a   Pizzini, P ^a   Tripepi, R ^a   Tripepi, G ^a   De Caterina, R ^b   Zoccali, C ^a  

^a Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Advanced glycation end product; Chronic kidney disease; Left ventricular hypertrophy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 84865737611     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.11.008     Document Type: Article

References (41)

1. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
2. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005, 83:876-886.
3. Thornalley P.J. Advanced glycation end products in renal failure. J Ren Nutr 2006, 16:178-184.
4. Thomas M.C., Tsalamandris C., MacIsaac R., Medley T., Kingwell B., Cooper M.E., et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 2004, 66:1167-1172.
5. Jandeleit-Dahm K.A., Lassila M., Allen T.J. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann N Y Acad Sci 2005, 1043:759-766.
6. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004, 279:50019-50024.
7. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998, 4:1025-1031.
8. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070-1077.
9. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
10. Basta G., Leonardis D., Mallamaci F., Cutrupi S., Pizzini P., Gaetano L., et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010, 77:225-231.
11. Candido R., Forbes J.M., Thomas M.C., Thallas V., Dean R.G., Burns W.C., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003, 92:785-792.
12. Zoccali C., Mallamaci F., Asahia K., Benedetto F.A., Tripepi G., Tripepi R., et al. Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 2001, 14:293-298.
13. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int 2002, 80(Suppl.):35-38.
14. Perticone F., Maio R., Ruberto C., Cassano S., Tripepi G., Perticone M., et al. Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertension. Am J Kidney Dis 2008, 52:74-84.
15. Zoccali C., Benedetto F.A., Mallamaci F., Tripepi G., Giacone G., Cataliotti A., et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001, 12:2768-2774.
16. Moe S., Drüeke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
17. Levey A.S., Greene T., Kusek J.W., Beck G.L. Modification of Diet in Renal Disease (MDRD) Study Group. a simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000, 11:155A.
18. de Simone G., Devereux R.B., Daniels S.R., Koren M.J., Meyer R.A., Laragh J.H. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995, 25:1056-1062.
19. Jager K.J., Zoccali C., Macleod A., Dekker F.W. Confounding: what it is and how to deal with it. Kidney Int 2008, 73:256-260.
20. Amann K., Rychlík I., Miltenberger-Milteny G., Ritz E. Left ventricular hypertrophy in renal failure. Kidney Int Suppl 1998, 68:S78-S85.
21. Glassock R.J., Pecoits-Filho R., Barberato S.H. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009, 4(Suppl. 1):S79-S91.
22. London G.M. The concept of ventricular/vascular coupling: functional and structural alterations of the heart and arterial vessels go in parallel. Nephrol Dial Transplant 1998, 13:250-253.
23. Benedetto F.A., Mallamaci F., Tripepi G., Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001, 12:2458-2464.
24. Stein G., Busch M., Müller A., Wendt T., Franke C., Niwa T., et al. Are advanced glycation end products cardiovascular risk factors in patients with CRF?. Am J Kidney Dis 2003, 41:S52-S56.
25. Suliman M.E., Heimbürger O., Bárány P., Anderstam B., Pecoits-Filho R., Rodríguez Ayala E., et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003, 14:1614-1622.
26. Koyama H., Yamamoto H., Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007, 13:625-635.
27. Aleshin A., Ananthakrishnan R., Li Q., Rosario R., Lu Y., Qu W., et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signalling in a murine model. Am J Physiol Heart Circ Physiol 2008, 294:H1823-H1832.
28. Sakaguchi T., Yan S.F., Yan S.D., Belov D., Rong L.L., Sousa M., et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003, 111:959-972.
29. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
30. Bierhaus A., Haslbeck K.M., Humpert P.M., Liliensiek B., Dehmer T., Morcos M., et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin super-family. J Clin Invest 2004, 114:1741-1751.
31. Bierhaus A., Humpert P.M., Stern D.M., Arnold B., Nawroth P.P. Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 2005, 1043:676-680.
32. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.
33. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
34. Kalousová M., Hodková M., Kazderová M., Fialová J., Tesar V., Dusilová-Sulková S., et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006, 47:406-411.
35. Kalousova M., Bartosova K., Zima T., Skibová J., Teplan V., Viklický O. Pregnancy-associated plasma protein a and soluble receptor for advanced glycation end products after kidney transplantation. Kidney Blood Press Res 2007, 30:31-37.
36. Franke S., Muller A., Sommer M., Busch M., Kientsch-Engel R., Stein G. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 2003, 59:88-97.
37. Koyama H., Shoji T., Fukumoto S., Shinohara K., Shoji T., Emoto M., et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 2007, 27:147-153.
38. Nielsen J.M., Kristiansen S.B., Norregaard R., Andersen C.L., Denner L., Nielsen T.T., et al. Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 2009, 11:638-647.
39. Koyama Y., Takeishi Y., Arimoto T., Niizeki T., Shishido T., Takahashi H., et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007, 13:199-206.
40. Koyama Y., Takeishi Y., Niizeki T., Suzuki S., Kitahara T., Sasaki T., et al. Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 2008, 14:133-139.
41. Mallamaci F, Parlongo G, Catalano C, Puntorieri E, Zoccali C. Inflammation in chronic kidney disease: a pathophysiological and clinical overview. Nutr Ther Metab, in press.